Many paediatric patients with cancer experience significant chemotherapy side effects. Predisposition to drug reactions is governed by single nucleotide polymorphisms (SNPs). We performed a systematic review of the literature from 2006 through 2016. Outcomes of interest included patient characteristics, cancer type drug of interest, genes investigated, toxicity identified and genetic polymorphisms implicated. The primary toxicities studied were neurotoxicity cardiotoxicity, osteonecrosis, and thromboembolism and hypersensitivity reactions. The retrieved studies were grouped according to toxicity reported and SNP associations. This review highlights the discoveries to date in pharmacogenomics and paediatric oncology along with highlighting some of the important limitations in the area.
INTRODUCTION
An individual's genetic makeup is a major contributor to the development of an adverse drug reaction (ADR). Pharmacogenomics is the study of how variations in single nucleotide polymorphisms (SNPs), together with insertion and deletion polymorphisms, contribute to inter-individual differences in efficacy and toxicity of drugs, thereby affecting clinical response. 1 This is pertinent in cancer therapy, as most regimens include high-dose administration of therapy with highly toxic profiles that may result in a wide variety of complications. ADRs are often a result of direct toxicity in normal healthy cells due to the low specificity displayed by chemotherapeutic drugs and occur more frequently with treatment intensification. Unsurprisingly, chemotherapy toxicity is a common cause of morbidity and mortality in most paediatric cancer patients, and a frequent cause of mid-and long-term sequelae. 2 The gravity of paediatric oncology ADRs is best illustrated by anthracycline cardiotoxicity (ACT). Anthracyclines are a potent chemotherapeutic drug and part of over 50% of curative regimens. 3 Abbreviations: 6-MP, 6-mercaptopurine; ABCC, ATP binding cassette subfamily C member; ACT, anthracycline cardiotoxicity; ADR, adverse drug reaction; ALL, acute lymphoblastic leukaemia; CEP72, centrosomal protein 72; CGA, candidate gene approach; COMT, catechol-O-methyltransferase; CTCAE, Common Terminology Criteria for Adverse Events; GCR, glucocorticoid receptor; GWAS, genome-wide association study; IC, inclusion criteria; MTHFR, methylenetetrahydrofolate reductase; RFC, replication factor C; SLC, solute carrier; SLCO1B1, Solute carrier organic anion transporter family member 1B1; SNP, single nucleotide polymorphism; TPMT, thiopurine methyltransferase
The ADR most commonly related to anthracycline exposure is severe ACT, affecting more than 7% of patients. 4 ACT results in free radical damage and causes cardiomyocyte death. 5 It often presents months or years post-treatment, and no screening methods exist to identify atrisk individuals. Whilst current treatment regimens can slow or stabilise this disease, in the event of congestive cardiac failure patients can be predisposed to sudden cardiac death. The cardiovascular mortality rates are > 10-fold higher than aged matched controls in paediatric oncology patients necessitating the need to investigate cardiovascular ADR further. 6, 7 The successful application of pharmacogenetics research to clinical outcome in paediatric oncology is demonstrated by genetic polymorphisms within the thiopurine methyltransferase (TPMT) gene. TPMT is the main gene regulator of the active and inactive metabolites of the drug 6-mercaptopurine (6-MP). Intracellularly, 6-MP can either be metabolised by hypoxanthine phosphoribosyltransferase 1 (HPRT1), resulting in synthesis of active cytotoxic metabolites that incorporate into DNA or RNA to induce cell death, or be inactivated if methylated by TPMT to methyl-MP. Previous studies have shown that TPMT activity is highly variable among individuals. Three variant alleles, TPMT*2 (G238C), TPMT*3A (G460A and A719G) and TPMT*3C (A719G), account for more than 95% of the inherited variability in TPMT enzyme activity. 8 It has become the gold standard of practice to determine the germline genetic variations in TPMT among paediatric cancer patients at the start of therapy, so dose adjustments can be anticipated. TPMT is now the only pharmacogenetics marker in acute lymphoblastic leukaemia (ALL) with guidelines for drug dosing according to one's TPMT genotype.
The clinical application of pharmacogenomics within paediatric oncology is a fast moving subspecialty. The primary aim of this review was to evaluate the current understanding of genomic associations across a range of frequent chemotherapy ADR including vincristine neuropathy, methotrexate encephalopathy, ACT, glucocorticoid-induced osteonecrosis, asparaginase hypersensitivity and thromboembolism.
METHODS
This review was conducted according to the guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement (PRISMA). 9 
Eligibility criteria
Randomised, non-randomised and cohort studies were included. Studies had to involve paediatric or adolescent patients aged 18 years and below, who had been diagnosed with cancer and had undergone chemotherapy. In addition studies had to investigate genetic polymorphisms in the study participants with the outcome measures including drug-related toxicity. Articles had to be available in full text and published in English no earlier than 2006. Studies were included if >75% of participants met eligibility criteria. Secondary screening was performed on articles short listed during initial screening. Articles were removed during secondary screening if the identified toxicity included neutropenia, infection or neurocognitive outcomes as these outcomes were thought to have many contributing factors and could confound genetic findings. In addition studies involving TPMT were excluded on secondary screening as this genetic variant screening is already standard of care within the paediatric oncology setting.
Search methods
Published scientific literature on OvidSP Medline, OvidSP Embase, PubMed and Cochrane Library from 2006 to 2016 was considered for inclusion. Limits were applied for English language, and search terms indicative of 'cancer' , 'neoplasm' or 'malignancy' , with their alternatives and truncations, AND 'toxicity' , or 'adverse effect' , or 'side effect' , with their alternatives, AND 'pharmacogenetics' , 'genetic polymorph' , 'genotype' , or 'genetic variability' , with their alternatives AND 'newborn' , 'neonate' , 'infant' , 'pre-schooler' , 'child' , 'adolescent' , 'teen' , 'youth' , or 'paediatric' , with their alternatives were used. Letters, practice guidelines, comments and editorial articles were excluded.
Reference lists of included studies and relevant review articles were checked to ensure all studies had been obtained. Citation tracking of included articles was completed using EndNote. All studies were exported to and managed in EndNote Version 7 for Mac. Three hundred thirty-five duplicates were removed using the 'Find Duplicates' function (EndNote) and manual duplicate screening. Screening of the titles and abstracts for relevance assessed eligibility of retrieved papers. From the relevant studies, full-text papers were assessed for inclusion and exclusion criteria independently by two authors.
Article appraisal
Data were extracted by one reviewer on study design, participant characteristics, setting, sample size, participant numbers, genomic analysis and reported ADRs (i.e., neurotoxicity, cardiotoxicity, osteonecrosis, and thromboembolism and hypersensitivity reaction). The outcome measures to assess toxicity of ADR were categorised as either compliant with the Common Terminology Criteria for Adverse Events (CTCAE) by the National Cancer Institute 10 or according to the World Health Organisation criteria. 11 Furthermore, the studies were categorised based on toxicity identified and tumour group. In addition, how participants were enrolled within cohort studies, and the genetic profiling methods that were utilised in studies, have been reported as these are likely to impact the results. A standardised Excel form was used to extract information on study demographics, patient characteristics, cancer type, chemotherapeutic drug of interest, genetic profiling method, genes investigated, toxicity identified and genetic polymorphisms identified. A second investigator reviewed the extracted data and disagreements were discussed until a consensus was reached.
Data analysis
The primary outcomes of interest were neurotoxicity (neuropathy and encephalopathy), cardiotoxicity, osteonecrosis, thromboembolism and hypersensitivity reactions. These toxicities were chosen as they are common in paediatric patients undergoing chemotherapy and formed the basis of further retrospective research undertaken by the author at The Royal Children's Hospital, Australia. Secondary outcomes included diarrhoea, gastrointestinal toxicity, glucose metabolism abnormalities, hepatotoxicity (including hyperbilirubinemia), hypertension, mucositis, myelotoxicity (anaemia, granulocytopenia, leukopenia and thrombocytopenia), nephrotoxicity, pancreatitis, skin toxicity, stomatitis and vomiting where recorded but not reported upon this review. Initial screening for inclusion criteria (IC) was performed manually by developing groups on EndNote and articles were excluded if they did not meet all the IC. Excluded articles were placed in the following groups: (1) adult participants aged over 21 years if <75% of the study population were paediatric, (2) non-human subjects, (3) not related to cancer, (4) had not undergone chemotherapy, (5) descriptive literature reviews, (6) no genetic polymorphisms investigated and (7) no drug-related toxicity investigated.
RESULTS

Study selection
The electronic search of OvidSP Medline, OvidSP Embase, PubMed and the Cochrane Library identified 1,471 citations, of which 1,136 studies were identified after excluding duplicates. Of this 1,136 F I G U R E 1 PRISMA flow chart of study selection studies, 243 articles were identified as being relevant to this review (see Figure 1 ). Secondary selection reviewed full texts to establish relevance of these 243 articles to study aims. Neutropenia or infection and neurocognitive outcomes were specifically searched for and these studies were excluded as they had many contributing factors and a clear link with genetic polymorphisms cannot be established.
Studies investigating the TPMT gene were also excluded as previously addressed. When duplicate reports of the same study were identified, the most recent and/or complete publication was chosen for review.
Conference abstracts and posters were excluded as they did not yield sufficient information to fit our IC, and often reported an already included study. After secondary screening, 86 articles were deemed relevant and selected for review.
Study characteristics
The systemic review of the 86 studies comprised 71 cohort studies, three case reports, two systematic reviews and two meta-analyses. Of the cohort studies, 38 were retrospective and 33 were prospective.
Forty-nine studies were single centre, three were dual centre and 20
were multi-centre studies. Thirty-two of the cohort studies were conducted in Europe (including one study done across Austria, Germany and Switzerland), 17 in the Americas (North and South), 11 in Asia, five in Canada, three in Africa and one in Australasia. Sixty-two studies utilised candidate gene approach (CGA) to identify potential genes that confer toxicity susceptibility based on existing literature, while nine used genome-wide association study (GWAS). Forty-two studies used a published or adapted version of the CTCAE by the National Cancer Institute 10 for grading toxicities, while 11 used the World Health Organisation criteria. 11 Other studies used a mix of methods to grade toxicities. The three case reports each described a single patient's toxicity outcomes. [12] [13] [14] All three studies utilised CGA to identify genes of interest and used descriptive reports of toxicities without clearly defined grading criteria.
The two systematic reviews 15, 16 and two meta-analyses 17,18 displayed large-scale heterogeneity across various comparator domains, including the number of studies included, tumour type studied and the toxicity being assessed.
Outcomes
Key outcomes from cohort studies are provided in a tabulated synthesis according to the toxicity identified including neurotoxicity, cardiotoxicity, osteonecrosis, hypersensitivity to aspariginase and ototoxicity (Tables 1-5 and Supplementary Tables 1-7) . None of the studies to date investigated thromboembolism as a toxicity, although this is a primary outcome of interest for this review.
Neurotoxicity
Twelve cohort studies and three case reports reported neurotoxicity outcomes across the globe (see Tables 1 and 2 ). Four studies looked at cytochrome p450 (CYP3A) and its association with neurotoxicity.
Three studies found no association [19] [20] [21] and one found that CYP3A5 expression was associated with the toxicity. 22 Two studies investigated centrosomal protein 72 (CEP72) with variable findings. Diouf et al. 23 using a GWAS in two separate cohorts found rs924607 associated with neurotoxicity, after multivariate analysis and imputation of the GWAS to better define the statistical significance of the SNP. In contrast, Guitierrez-Carnino et al. 24 found no association with the same SNP in a smaller, retrospective study that only assessed toxicity over the first month of therapy. ATP binding cassette subfamily B member (ABCB1) was studied in five studies 14, 18, [25] [26] [27] with two demonstrating protective effects from rs4728709 and rs10244266. 18, 25 Of these, [12] [13] [14] although these findings were not replicated across the cohort studies.
Cardiotoxicity
Ten cohort studies reported cardiotoxicity outcomes across Europe and North America (Table 3) . 3, [31] [32] [33] [34] [35] [36] [37] [38] [39] Two studies incorporated the ATP binding cassette subfamily C member (ABCC) family, with a risk associated with rs7627754, 31 rs3743527 TT genotype and in combination with the rs246221 TC/TT genotype. 34 Blanco et al. found the expression of carbonyl reductase 3 (CBR3) was associated with cardiotoxicity, 36 whilst no association was found in the authors' previous study. 35 Visscher et al. conducted two multi-centre, prospective studies in different cohorts in Canada and Holland, looking at the solute carrier (SLC) family. The first study 37 revealed three SNPs (rs7853758, rs885004 and rs4877847) that were significant for cardiotoxicity risk, whilst the second study 38 found four additional SNPs (rs4982753, rs4149178, rs12882406 and rs12896494) to be associated. The SNPs found in Visscher et al.'s study were validated within the same study using a European cohort. 38 Only one study observed a cardio protective effect through rs1799983 in nitric oxide synthase 3 (NOS3) 31 and this has not been validated in further studies.
Osteonecrosis
Four cohort studies reported outcomes in osteonecrosis across North America ( 
Hypersensitivity to asparaginase
Three cohort studies reported hypersensitivity to asparaginase outcomes across Europe and North America (Table 5) . Two studies investigated the glutamate inotropic receptor AMPA type subunit 1 (GRIA1), with both finding association with multiple risk variants (rs2055083, rs707176, rs4958351, rs10070447, rs4958676, rs6889909 and rs6890057). 43, 44 Interestingly, rs4958351 was found to be both protective 43 and a risk variant. 44 Additionally, Ben Tanfous et al. investigated the asparagine synthetase (ASNS) and found rs3832526 to be associated with asparaginase hypersensitivity. 45 
Ototoxicity
Ten cohort studies reported ototoxicity outcomes across Asia, Europe and North America (Supplementary Table S7 ). While all studies inves- were highly associated with cisplatin-induced deafness. 46 This finding was further confirmed in a replication cohort of 112 patients from paediatric oncology centres throughout Canada. 46 In a study performed protocols, none of the TPMT or COMT genetic variation was replicated to cisplatin ototoxicity in the same described variants. 48 The German study by Lanvers-Kaminsky et al. also failed to show replication of significance for both TPMT (rs12201199) and COMT (rs9332377) as did the initial Dutch cohort described by Hagleitner et al. 49 However, in a different Spanish replication cohort described by Hagleitner et al., the same SNPs were found to be statistically significant. Finally, Rednam et al.'s study found that GSTP1 (rs1695) was associated with ototoxicity requiring hearing aids in patients with medulloblastoma;
however, this finding cannot be attributed to cisplatin alone as the patients also received radiotherapy. 50 
Myelotoxicity
Twenty-three cohort studies reported myelotoxicity outcomes across Asia, Europe, North America and South America (Supplementary Table S6 ). Fifteen studies investigated MTHFR, with two finding no association. 51, 52 Nine studies found the C677T mutation in MTHFR contributed to myelotoxicity. [53] [54] [55] [56] [57] [58] [59] [60] The A1298C SNP was also associated with myelotoxicity in three studies 53, 54, 57 although two studies found this polymorphism to be protective. 61, 62 Only a single study associated the G80A SNP with myelotoxicity. 63 Two studies investigated the replication factor C (RFC) gene. Salazar 
Nephrotoxicity
Six cohort studies reported nephrotoxicity secondary to methotrexate, with outcomes reported across Europe and Asia (Supplementary Table S1 )). Three studies investigated MTHFR and found C677T SNP was associated with nephrotoxicity. 55, 64, 65 Of these, two also found an association with A1298C. 64, 65 Two further studies investigated solute carrier organic anion transporter family member 1B1
(SLCO1B1) with rs11045879 66 and rs4149035 18 associated with nephrotoxicity. 
TA B L E 2 Single nucleotide polymorphisms associated with non-vincristine neurotoxicity
Gastrointestinal toxicity
Seventeen cohort studies reported gastrointestinal toxicity outcomes across Asia, Europe and North America (Supplementary Table   S2 ). Of the three studies investigating MTHFR, two found C677T to be associated with toxicity. 61, 67 Three studies investigated the ABCC gene family, in which each study found SNPs to be associated with gastrointestinal toxicity. 66, [68] [69] [70] Two studies found the identical rs11045879 SNP of SLCO1B1 associated with gastrointestinal toxicity. 66, 71 Furthermore, two studies demonstrated association with the GG genotype of RFC1. 64, 72 Of the two studies investigating the gene family SLC, one study found a protective SNP, 73 whereas the other study found an SNP associated with gastrointestinal toxicity. 66 Additionally, both studies investigating thymidylate synthetase (TYMS) found an associated protective SNP. 56, 74 
Hepatotoxicity
Nineteen cohort studies reported hepatotoxicity outcomes across Asia, Europe, North America and South America (Supplementary 
Other toxicities
Five cohort studies reported toxicity outcomes including pancreati- SNPs associated with cytotoxicity in patient-derived cell lines through GWAS. 81 
Systematic reviews and meta-analyses
Four studies contributed secondary literature to this review. Both meta-analyses found no association between the MTHFR 18 and RFC1 17 genes, respectively, with multiple toxicities. Of the systematic reviews, one study 15 identified multiple SNPs associated with cardiotoxicity, whereas the other study found reduced expression related to neurotoxicity. 
TA B L E 3 Single nucleotide polymorphisms associated with cardiotoxicity
Country
Study characteristics
DISCUSSION
This systematic review was conducted to evaluate the genetic polymorphisms associated with chemotherapy toxicity in paediatric oncology patients. Literature on this topic is conflicting with great heterogeneity among the genes and subsequent SNPs investigated. The approach to define toxicity was also variable that may have further nor UGT1A6 is expressed in the heart. The controversy raised by recommending guidelines for ACT based on pharmacogenomic studies highlights the need for prospective studies to be performed prior to recommendations being proffered and appropriate functional models to be sufficiently investigated prior to these recommendations.
Furthermore, supporting Craig et al. reluctance to bring routine screening directly into clinic is the conflicting GWAS results that can exist amongst cohorts screening for the same toxicity. This is demonstrated for the studies investigating cisplatin ototoxicity. Three separate cohorts have been described in which the SNPs associated with TPMT (rs12201199, rs1142345 and rs1800460) were found to be related to ototoxicity. 46, 47 Asp, aspariginase, ret, retrospective; pro, prospective.
significant. 48 This lack of association for TPMT (rs12201199) and COMT (rs9332377) was mirrored in the German study by LanversKaminsky et al. 83 and the initial Dutch cohort described by Hagleitner et al. 49 This example illustrates the need for collaborative multiinstitute trials but also the requirement for vigorous functional validation of any described variants to ensure their contribution to the associated toxicity.
Only one prospective pharmacogenomic study in paediatric oncology has found an inherited polymorphism that resulted in an increased risk and severity of an ADR with satisfactory functional validation that is one proposed way to functionally validate a genomic finding. 84, 85 In the Diouf et al. 23 The well-designed, sufficiently powered prospective studies utilising GWAS with an internationally recognised toxicity-grading approach are thus needed to further confirm the findings of SNP associations in paediatric cohorts.
